- Poster presentation
- Open Access
Analysis of interleukin-13 receptor alpha2 expression as a prognostic biomarker in surgically resected pancreatic cancer patients
Journal for ImmunoTherapy of Cancer volume 3, Article number: P88 (2015)
IL-13Rα2 is recognized as one of the candidate genes significantly associated with pancreatic cancer risk. Previously, we have demonstrated that IL-13Rα2 is over-expressed in ~70% of human pancreatic cancer samples. We have also shown that IL-13 can mediate invasion and metastasis of human pancreatic cancer cells through IL-13Rα2 both in vitro and in an in vivo tumor models. Based on these results, we hypothesized that IL-13Rα2 expression in pancreatic cancer may be related to overall survival of subjects following surgical resection.
Between 1996 and 2012 we obtained 107 samples from NTT Medical Center Tokyo and 129 samples from Yokohama City University Hospital, Japan. Immunohistochemical staining (IHC) for IL-13Rα2 was performed and the results analyzed independently by each hospital's pathologists. The level of IL-13Rα2 staining intensity (0 to 3+) was used to categorize the specimens as strong (2+ and 3+) or weak expressers (0 and 1+).
By Kaplan-Meier method, subjects expressing strong IL-13Rα2 on their tumors survived significantly shorter duration compared to those with weak expression (p = 0.024). Further analysis demonstrated that the level of IL-13Rα2 expression was inversely correlated with survival time and invasion, but not with tumor staging and histological grade. We are currently examining the correlation between a variety of other clinical factors and IL-13Rα2 expression using Spearman's rank correlation test.
In summary, our preliminary results suggest that IL-13Rα2 expression has an important role in prognosis and may be critical in overall survival of pancreatic cancer patients.
About this article
Cite this article
Fujisawa, T., Shimamura, T., Joshi, B.H. et al. Analysis of interleukin-13 receptor alpha2 expression as a prognostic biomarker in surgically resected pancreatic cancer patients. j. immunotherapy cancer 3, P88 (2015) doi:10.1186/2051-1426-3-S2-P88
- Pancreatic Cancer
- Pancreatic Cancer Cell
- Human Pancreatic Cancer
- Pancreatic Cancer Patient
- Human Pancreatic Cancer Cell